Antibodies

14 June 2014

U.S. FDA Approves Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Expanded Use in Head and Neck Cancer Sentinel Lymph Node Biopsy

13 June 2014

TG Therapeutics’ TG-1101 (Ublituximab) in Combination With Ibrutinib Demonstrates Compelling Clinical Activity and Safety Profile in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

13 June 2014

OncoMed Voluntarily Halts Enrollment and Dosing in Phase 1 Vantictumab and Fzd8-Fc Trials

12 June 2014

Oncobiologics launches Phase I Clinical Trial for ONS-3010 Biosimilar version of Humira

12 June 2014

Phase 3 Data Demonstrate Comparability of Epirus’ BOW015 to Remicade® for Treatment of Rheumatoid Arthritis

12 June 2014

Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine

12 June 2014

Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR

11 June 2014

AVERT Trial Demonstrates High Rates of DAS-defined Remission with Orencia® (abatacept) in Combination with Methotrexate (MTX) in Adult Patients with Early Rheumatoid Arthritis (RA)

11 June 2014

Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial

11 June 2014

EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

10 June 2014

Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer

7 June 2014

ImaginAb Presents Initial Phase I/IIa Results for Prostate Imaging Agent at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

3 June 2014

AstraZeneca’s MedImmune Presents Encouraging Immunotherapy Data at ASCO 2014

3 June 2014

Immunomedics Announces Objective Responses in Five Types of Solid Cancer With IMMU-132

3 June 2014

Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting

3 June 2014

Lilly’s CYRAMZA™ (ramucirumab) Significantly Improves Overall Survival In Phase III Non-Small Cell Lung Cancer Study

3 June 2014

Celldex Therapeutics’ Varlilumab Continues to Demonstrate Very Favorable Profile

2 June 2014

HealthCare Pharmaceuticals Announces ASCO Presentation of DKN-01 Clinical Study in Non-Small Cell Lung Cancer and First Patients Dosed in Clinical Study for DKK1+ Esophageal Cancer

2 June 2014

Immunomedics Reports IMMU-130 is Active in Patients With Irinotecan-Refractory Colorectal Cancer

2 June 2014

First Presentation of Data for Pembrolizumab, Merck’s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014

2 June 2014

Data on Merck’s Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ASCO 2014

2 June 2014

One- & Two-Year Survival Rates of 94% and 88% Announced from Phase 1b Trial of Investigational PD-1 Checkpoint Inhibitor Nivolumab and Yervoy® (ipilimumab) in Advanced Melanoma; Ongoing Phase 2/3 Trials to Confirm Results

2 June 2014

Phase 3 Study Evaluating Yervoy® (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free Survival

2 June 2014

Immunomedics Reports Final Efficacy Results of Phase Ib Trial With Yttrium-90-Labeled Clivatuzumab Tetraxetan in Patients With Metastatic Pancreatic Cancer

2 June 2014

Immunomedics Reports Development of Improved Cancer Immunotherapy at the 2014 Annual Meeting of the American Society of Clinical Oncology

2 June 2014

Seattle Genetics Presents Data from Phase 1 Clinical Trial of Antibody-Drug Conjugate (ADC) SGN-CD19A in Non-Hodgkin Lymphoma at ASCO Annual Meeting

2 June 2014

First Presentation of Early Data for Pembrolizumab (MK-3475), Merck’s Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014

2 June 2014

ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data with Sanofi’s SAR3419 in Diffuse Large B-Cell Lymphoma

2 June 2014

New Detailed Phase 3 Data Show Amgen’s Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With A Rare And Serious Genetic Disorder That Causes High Cholesterol

1 June 2014

Seattle Genetics Highlights Data from Multiple Collaborator Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Mesothelin-Targeted Immunotherapy Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Adalimumab (Humira) Biosimilars Pipeline Review